© Reuters. FILE PHOTO: A test tube is seen in front of displayed Biogen logo in this illustration taken, December 1, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) – Biogen Inc (NASDAQ:) said on Tuesday its Chief Executive Officer Michel Vounatsos will step down and the company has started a search for a successor.
The company reported a 26% fall in quarterly profit as sales of its blockbuster multiple sclerosis drug Tecfidera continued to be pressured by cheaper versions of the treatment.
Be the first to comment